The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FDA grants Orphan Drug Designation to BI-1206 for patients with previously treated MCL
On 30 January 2019, BI-1206, a monoclonal antibody that selectively binds to CD32B in B cells, was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL).
The Orphan Drug Designation granted by the FDA occurs as BI-1206 is currently in a dose-escalation, consecutive-cohort, open-label phase I/IIa trial (NCT03571568). This trial is evaluating BI-1206 in combination with rituximab in patients with R/R B cell non-Hodgkin lymphoma, including MCL, follicular lymphoma and marginal zone lymphoma.
According to the drug manufacturers, the Orphan Drug Designation granted to BI-1206 by the FDA could provide evidence “to support the use of BI-1206 in combination with rituximab”, which would provide a future treatment option for patients with MCL.
References